应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
AVBP ArriVent BioPharma
交易中 12-31 14:45:45 EST
20.29
-0.43
-2.08%
最高
20.91
最低
20.21
成交量
30.21万
今开
20.60
昨收
20.72
日振幅
3.35%
总市值
8.38亿
流通市值
3.71亿
总股本
4,128万
成交额
616.58万
换手率
1.65%
流通股本
1,829万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
ArriVent BioPharma宣布全球关键性3期Alpacca试验首名患者接受治疗，评估Firmonertinib用于EGFR PACC突变非小细胞肺癌的一线治疗
美股速递 · 2025-12-22
ArriVent BioPharma宣布全球关键性3期Alpacca试验首名患者接受治疗，评估Firmonertinib用于EGFR PACC突变非小细胞肺癌的一线治疗
ArriVent BioPharma预计2026年初公布全球三期临床试验的关键数据
美股速递 · 2025-11-10
ArriVent BioPharma预计2026年初公布全球三期临床试验的关键数据
Arrivent Biopharma, Inc.盘中异动 大幅下挫5.04%
市场透视 · 2025-10-30
Arrivent Biopharma, Inc.盘中异动 大幅下挫5.04%
Arrivent Biopharma, Inc.盘中异动 快速下挫5.00%
市场透视 · 2025-09-18
Arrivent Biopharma, Inc.盘中异动 快速下挫5.00%
Arrivent Biopharma, Inc.2025财年第二财季实现净利润-31.40百万美元，同比减少43.58%
市场透视 · 2025-08-18
Arrivent Biopharma, Inc.2025财年第二财季实现净利润-31.40百万美元，同比减少43.58%
异动解读 | ArriVent BioPharma盘中大涨5.13%，尽管季度业绩未达预期
异动解读 · 2025-08-13
异动解读 | ArriVent BioPharma盘中大涨5.13%，尽管季度业绩未达预期
异动解读 | ArriVent BioPharma股价盘中大跌5.12%，花旗下调目标价
异动解读 · 2025-08-12
异动解读 | ArriVent BioPharma股价盘中大跌5.12%，花旗下调目标价
Arrivent Biopharma, Inc.2024财年实现净利润-80.49百万美元，同比减少16.10%
市场透视 · 2025-03-09
Arrivent Biopharma, Inc.2024财年实现净利润-80.49百万美元，同比减少16.10%
Arrivent Biopharma, Inc.盘中异动 大幅下跌5.51%报23.84美元
市场透视 · 2025-02-27
Arrivent Biopharma, Inc.盘中异动 大幅下跌5.51%报23.84美元
Arrivent Biopharma, Inc.盘中异动 大幅跳水7.57%报25.02美元
市场透视 · 2025-02-24
Arrivent Biopharma, Inc.盘中异动 大幅跳水7.57%报25.02美元
Arrivent Biopharma, Inc.盘中异动 股价大涨5.24%报28.00美元
市场透视 · 2025-02-18
Arrivent Biopharma, Inc.盘中异动 股价大涨5.24%报28.00美元
Arrivent Biopharma, Inc.盘中异动 急速下挫5.11%
市场透视 · 2025-02-07
Arrivent Biopharma, Inc.盘中异动 急速下挫5.11%
Arrivent Biopharma, Inc.盘中异动 早盘大幅拉升5.77%报26.77美元
市场透视 · 2025-01-22
Arrivent Biopharma, Inc.盘中异动 早盘大幅拉升5.77%报26.77美元
【乐普生物-B(02157.HK)就创新型ADC MRG007订立独家许可协议】乐普生物-B(02157.HK)发布公告，于2025年1月22日，公司与ArriVent Biopharma, Inc.(该公司于纳斯达克全球市场上市(股票代码：AVBP))订立独家许可协议。据此协议，公司向ArriVent授予独家许可，以在全球范围内(大中华地区除外)开发及商业化集团创新型抗体偶联药物MRG007。
金融界 · 2025-01-22
【乐普生物-B(02157.HK)就创新型ADC MRG007订立独家许可协议】乐普生物-B(02157.HK)发布公告，于2025年1月22日，公司与ArriVent Biopharma, Inc.(该公司于纳斯达克全球市场上市(股票代码：AVBP))订立独家许可协议。据此协议，公司向ArriVent授予独家许可，以在全球范围内(大中华地区除外)开发及商业化集团创新型抗体偶联药物MRG007。
Arrivent Biopharma, Inc.盘中异动 早盘快速上涨5.19%
市场透视 · 2025-01-21
Arrivent Biopharma, Inc.盘中异动 早盘快速上涨5.19%
Arrivent Biopharma, Inc.盘中异动 早盘快速下挫5.18%报23.63美元
市场透视 · 2025-01-16
Arrivent Biopharma, Inc.盘中异动 早盘快速下挫5.18%报23.63美元
Arrivent Biopharma, Inc.盘中异动 急速拉升6.80%
市场透视 · 2025-01-15
Arrivent Biopharma, Inc.盘中异动 急速拉升6.80%
Arrivent Biopharma, Inc.盘中异动 大幅下挫5.06%报25.50美元
市场透视 · 2025-01-10
Arrivent Biopharma, Inc.盘中异动 大幅下挫5.06%报25.50美元
Arrivent Biopharma, Inc.盘中异动 股价大跌5.52%
市场透视 · 2025-01-07
Arrivent Biopharma, Inc.盘中异动 股价大跌5.52%
Arrivent Biopharma, Inc.盘中异动 下午盘快速下跌5.25%
市场透视 · 2024-12-13
Arrivent Biopharma, Inc.盘中异动 下午盘快速下跌5.25%
加载更多
公司概况
公司名称：
ArriVent BioPharma
所属市场：
NASDAQ
上市日期：
--
主营业务：
Arrivent Biopharma, Inc.于2021年4月14日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，致力于差异化药物的识别、开发和商业化，以解决癌症患者未满足的医疗需求。该公司寻求利用团队深厚的药物开发经验，通过在患有癌症的患者中获得批准和商业化，最大限度地发挥先导开发候选药物呋莫替尼的潜力，并推进一系列新疗法，例如下一代抗体药物偶联物，最初的重点是实体瘤。
发行价格：
--
{"stockData":{"symbol":"AVBP","market":"US","secType":"STK","nameCN":"ArriVent BioPharma","latestPrice":20.29,"timestamp":1767210344240,"preClose":20.72,"halted":0,"volume":302105,"delay":0,"floatShares":18293400,"shares":41281361,"eps":-4.175792,"marketStatus":"交易中","change":-0.43,"latestTime":"12-31 14:45:45 EST","open":20.6,"high":20.905,"low":20.21,"amount":6165843.114315,"amplitude":0.033542,"askPrice":20.29,"askSize":83,"bidPrice":20.26,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.175792,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1767214800000},"marketStatusCode":2,"adr":0,"listingDate":1706245200000,"exchange":"NASDAQ","adjPreClose":20.72,"postHourTrading":{"tag":"盘后","latestPrice":20.72,"preClose":20.72,"latestTime":"18:24 EST","volume":4888,"amount":101267.68,"timestamp":1767137087794},"volumeRatio":1.323461,"impliedVol":1.5981,"impliedVolPercentile":0.9837},"requestUrl":"/m/hq/s/AVBP","defaultTab":"news","newsList":[{"id":"1188104353","title":"ArriVent BioPharma宣布全球关键性3期Alpacca试验首名患者接受治疗，评估Firmonertinib用于EGFR PACC突变非小细胞肺癌的一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1188104353","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188104353?lang=zh_cn&edition=full","pubTime":"2025-12-22 21:01","pubTimestamp":1766408507,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma宣布全球关键性3期Alpacca试验的首名患者已接受治疗，该试验旨在评估Firmonertinib用于EGFR PACC突变非小细胞肺癌的一线治疗效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"1115786569","title":"ArriVent BioPharma预计2026年初公布全球三期临床试验的关键数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1115786569","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115786569?lang=zh_cn&edition=full","pubTime":"2025-11-10 21:17","pubTimestamp":1762780634,"startTime":"0","endTime":"0","summary":"ArriVent BioPharma预计将在2026年初公布关于外显子20插入突变非小细胞肺癌（NSCLC）全球三期临床试验的关键数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2579632281","title":"Arrivent Biopharma, Inc.盘中异动 大幅下挫5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579632281","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579632281?lang=zh_cn&edition=full","pubTime":"2025-10-30 03:33","pubTimestamp":1761766414,"startTime":"0","endTime":"0","summary":"北京时间2025年10月30日03时33分，Arrivent Biopharma, Inc.股票出现异动，股价急速跳水5.04%。Arrivent Biopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.71%。其相关个股中，Purple Biotech Ltd、Genenta Science Spa、Processa Pharmaceuticals, Inc.涨幅较大，Purple Biotech Ltd、Ernexa Therapeutics Inc.、Aditxt, Inc.较为活跃，换手率分别为4389.85%、2659.74%、481.55%，振幅较大的相关个股有Surrozen Inc C/Wts 01/08/2031 、Ernexa Therapeutics Inc.、Purple Biotech Ltd，振幅分别为139.33%、107.99%、93.83%。Arrivent Biopharma, Inc.公司简介：ArriVent BioPharma Inc是一家临床阶段的生物制药公司，致力于识别、开发和商业化差异化药物，以解决癌症患者未满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510300333349748f9a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510300333349748f9a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2568410340","title":"Arrivent Biopharma, Inc.盘中异动 快速下挫5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2568410340","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568410340?lang=zh_cn&edition=full","pubTime":"2025-09-18 03:31","pubTimestamp":1758137487,"startTime":"0","endTime":"0","summary":"北京时间2025年09月18日03时31分，Arrivent Biopharma, Inc.股票出现异动，股价急速跳水5.00%。Arrivent Biopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.02%。Arrivent Biopharma, Inc.公司简介：ArriVent BioPharma Inc是一家临床阶段的生物制药公司，致力于识别、开发和商业化差异化药物，以解决癌症患者未满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250918033127a4cc27c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250918033127a4cc27c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2560290730","title":"Arrivent Biopharma, Inc.2025财年第二财季实现净利润-31.40百万美元，同比减少43.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2560290730","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2560290730?lang=zh_cn&edition=full","pubTime":"2025-08-18 00:00","pubTimestamp":1755446451,"startTime":"0","endTime":"0","summary":"8月18日，Arrivent Biopharma, Inc.公布财报，公告显示公司2025财年第二财季净利润为-31.40百万美元，同比减少43.58%；其中营业收入为0.00美元，每股基本收益为-0.90美元。从资产负债表来看，Arrivent Biopharma, Inc.总负债19.64百万美元，其中短期债务98000.00美元，资产负债比为0.14，流动比率为0.13。机构评级：截至2025年8月18日，当前有10家机构对Arrivent Biopharma, Inc.目标价做出预测，其中目标均价为38.80美元，其中最低目标价为32.00美元，最高目标价为45.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250818000147a6eb4d77&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250818000147a6eb4d77&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"1124195036","title":"异动解读 | ArriVent BioPharma盘中大涨5.13%，尽管季度业绩未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1124195036","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124195036?lang=zh_cn&edition=full","pubTime":"2025-08-13 22:50","pubTimestamp":1755096650,"startTime":"0","endTime":"0","summary":"周三盘中，生物制药公司ArriVent BioPharma股价大涨5.13%，引起市场关注。这一涨势出现在公司发布了截至6月30日的季度财报之后，尽管财报显示业绩未达分析师预期。根据公司公布的财报，ArriVent BioPharma本季度调整后每股亏损90美分，高于分析师平均预期的70美分亏损。值得注意的是，尽管短期业绩欠佳，华尔街分析师对ArriVent BioPharma仍保持乐观态度。这种强烈的看好情绪可能是推动股价上涨的主要因素。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AVBP"],"gpt_icon":0},{"id":"1151844920","title":"异动解读 | ArriVent BioPharma股价盘中大跌5.12%，花旗下调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1151844920","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151844920?lang=zh_cn&edition=full","pubTime":"2025-08-12 22:37","pubTimestamp":1755009421,"startTime":"0","endTime":"0","summary":"8月12日周二，生物制药公司ArriVent BioPharma股价在盘中大跌5.12%，引发投资者关注。此次股价下跌主要受到华尔街分析师目标价调整的影响。花旗集团将ArriVent BioPharma的目标价从40美元大幅下调至33美元，降幅达17.5%。同一天，H.C. Wainwright研究公司反而将ArriVent BioPharma的目标价从40美元小幅上调至42美元。ArriVent BioPharma的这波股价波动凸显了生物科技股票的高风险特性。投资者在做出投资决策时，需要密切关注公司的研发进展、临床试验结果以及监管环境变化等因素。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AVBP"],"gpt_icon":0},{"id":"2518999428","title":"Arrivent Biopharma, Inc.2024财年实现净利润-80.49百万美元，同比减少16.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518999428","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518999428?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449670,"startTime":"0","endTime":"0","summary":"3月9日，Arrivent Biopharma, Inc.公布财报，公告显示公司2024财年净利润为-80.49百万美元，同比减少16.10%；其中营业收入为0.00美元，每股基本收益为-2.39美元。从资产负债表来看，Arrivent Biopharma, Inc.总负债17.29百万美元，其中短期债务162000.00美元，资产负债比为0.16，流动比率为0.14。机构评级：截至2025年3月9日，当前有4家机构对Arrivent Biopharma, Inc.目标价做出预测，其中目标均价为39.25美元，其中最低目标价为38.00美元，最高目标价为41.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000232abef983c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000232abef983c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVBP"],"gpt_icon":0},{"id":"2514508861","title":"Arrivent Biopharma, Inc.盘中异动 大幅下跌5.51%报23.84美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514508861","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514508861?lang=zh_cn&edition=full","pubTime":"2025-02-27 03:01","pubTimestamp":1740596500,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日03时01分，Arrivent Biopharma, Inc.股票出现波动，股价急速下跌5.51%。Arrivent Biopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.79%。其相关个股中，Enveric Biosciences, Inc.、Renovaro Inc.、Nkgen Biotech Inc C/Wts 31/05/2028涨幅较大，Enveric Biosciences, Inc.、Aeon Biopharma, Inc.、Organovo Holdings, Inc.较为活跃，换手率分别为6517.18%、288.23%、256.28%，振幅较大的相关个股有Enveric Biosciences, Inc.、Renovaro Inc.、Organovo Holdings, Inc.，振幅分别为194.07%、81.11%、52.76%。Arrivent Biopharma, Inc.公司简介：ArriVent BioPharma Inc 是一家临床阶段的生物制药公司，致力于识别、开发和商业化差异化药物，以解决癌症患者未满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227030140a255338d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227030140a255338d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2513419722","title":"Arrivent Biopharma, Inc.盘中异动 大幅跳水7.57%报25.02美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513419722","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513419722?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:32","pubTimestamp":1740407574,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时32分，Arrivent Biopharma, Inc.股票出现异动，股价大幅下跌7.57%。Arrivent Biopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。Arrivent Biopharma, Inc.公司简介：ArriVent BioPharma Inc 是一家临床阶段的生物制药公司，致力于识别、开发和商业化差异化药物，以解决癌症患者未满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223254a25214a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223254a25214a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2512165392","title":"Arrivent Biopharma, Inc.盘中异动 股价大涨5.24%报28.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512165392","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512165392?lang=zh_cn&edition=full","pubTime":"2025-02-18 22:33","pubTimestamp":1739889194,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日22时33分，Arrivent Biopharma, Inc.股票出现异动，股价急速拉升5.24%。截至发稿，该股报28.00美元/股，成交量1071股，换手率0.00%，振幅0.00%。Arrivent Biopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.08%。Arrivent Biopharma, Inc.公司简介：ArriVent BioPharma Inc 是一家临床阶段的生物制药公司，致力于识别、开发和商业化差异化药物，以解决癌症患者未满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021822331496279770&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021822331496279770&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2509788461","title":"Arrivent Biopharma, Inc.盘中异动 急速下挫5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509788461","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509788461?lang=zh_cn&edition=full","pubTime":"2025-02-07 03:08","pubTimestamp":1738868892,"startTime":"0","endTime":"0","summary":"北京时间2025年02月07日03时08分，Arrivent Biopharma, Inc.股票出现异动，股价急速下挫5.11%。Arrivent Biopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.32%。Arrivent Biopharma, Inc.公司简介：ArriVent BioPharma Inc 是一家临床阶段的生物制药公司，致力于识别、开发和商业化差异化药物，以解决癌症患者未满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207030812987cb59f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250207030812987cb59f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2505245007","title":"Arrivent Biopharma, Inc.盘中异动 早盘大幅拉升5.77%报26.77美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505245007","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505245007?lang=zh_cn&edition=full","pubTime":"2025-01-22 23:15","pubTimestamp":1737558905,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日23时15分，Arrivent Biopharma, Inc.股票出现波动，股价急速拉升5.77%。Arrivent Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.66%。Arrivent Biopharma, Inc.公司简介：ArriVent BioPharma Inc 是一家临床阶段的生物制药公司，致力于识别、开发和商业化差异化药物，以解决癌症患者未满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122231505a22bbbe4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122231505a22bbbe4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVBP","BK4139"],"gpt_icon":0},{"id":"2505194732","title":"【乐普生物-B(02157.HK)就创新型ADC MRG007订立独家许可协议】乐普生物-B(02157.HK)发布公告，于2025年1月22日，公司与ArriVent Biopharma, Inc.(该公司于纳斯达克全球市场上市(股票代码：AVBP))订立独家许可协议。据此协议，公司向ArriVent授予独家许可，以在全球范围内(大中华地区除外)开发及商业化集团创新型抗体偶联药物MRG007。","url":"https://stock-news.laohu8.com/highlight/detail?id=2505194732","media":"金融界","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505194732?lang=zh_cn&edition=full","pubTime":"2025-01-22 08:13","pubTimestamp":1737504821,"startTime":"0","endTime":"0","summary":"乐普生物-B(02157.HK)发布公告，于2025年1月22日，公司与ArriVent Biopharma, Inc.(该公司于纳斯达克全球市场上市(股票代码：AVBP))订立独家许可协议。据此协议，公司向ArriVent授予独家许可，以在全球范围内(大中华地区除外)开发及商业化集团创新型抗体偶联药物MRG007。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/22081347680310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4080","BK4139","ADC","AVBP","02157","BK4231","BK1161"],"gpt_icon":0},{"id":"2505270400","title":"Arrivent Biopharma, Inc.盘中异动 早盘快速上涨5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505270400","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505270400?lang=zh_cn&edition=full","pubTime":"2025-01-21 23:30","pubTimestamp":1737473413,"startTime":"0","endTime":"0","summary":"北京时间2025年01月21日23时30分，Arrivent Biopharma, Inc.股票出现波动，股价快速拉升5.19%。Arrivent Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为1.28%。Arrivent Biopharma, Inc.公司简介：ArriVent BioPharma Inc 是一家临床阶段的生物制药公司，致力于识别、开发和商业化差异化药物，以解决癌症患者未满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121233015abb354a6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121233015abb354a6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2503918717","title":"Arrivent Biopharma, Inc.盘中异动 早盘快速下挫5.18%报23.63美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503918717","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503918717?lang=zh_cn&edition=full","pubTime":"2025-01-16 22:40","pubTimestamp":1737038422,"startTime":"0","endTime":"0","summary":"北京时间2025年01月16日22时40分，Arrivent Biopharma, Inc.股票出现波动，股价急速下挫5.18%。截至发稿，该股报23.63美元/股，成交量2415股，换手率0.01%，振幅0.86%。Arrivent Biopharma, Inc.股票所在的生物技术行业中，整体跌幅为0.03%。Arrivent Biopharma, Inc.公司简介：ArriVent BioPharma Inc 是一家临床阶段的生物制药公司，致力于识别、开发和商业化差异化药物，以解决癌症患者未满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116224022abad51b5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250116224022abad51b5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2503647409","title":"Arrivent Biopharma, Inc.盘中异动 急速拉升6.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503647409","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503647409?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:32","pubTimestamp":1736951550,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时32分，Arrivent Biopharma, Inc.股票出现波动，股价急速上涨6.80%。Arrivent Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.77%。其相关个股中，Monte Rosa Therapeutics, Inc.、Exicure, Inc.、Generation Bio Co.涨幅较大，Windtree Therapeutics, Inc.、Phio Pharmaceuticals Corp.、Oncolytics Biotech Inc.较为活跃，换手率分别为185.07%、54.43%、35.46%，振幅较大的相关个股有Onconetix, Inc.、Klotho Neurosciences, Inc.、Eterna Therapeutics Inc.，振幅分别为14.29%、12.00%、11.55%。Arrivent Biopharma, Inc.公司简介：ArriVent BioPharma Inc 是一家临床阶段的生物制药公司，致力于识别、开发和商业化差异化药物，以解决癌症患者未满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223230a222fe2b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223230a222fe2b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2502898794","title":"Arrivent Biopharma, Inc.盘中异动 大幅下挫5.06%报25.50美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2502898794","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502898794?lang=zh_cn&edition=full","pubTime":"2025-01-10 23:13","pubTimestamp":1736522004,"startTime":"0","endTime":"0","summary":"北京时间2025年01月10日23时13分，Arrivent Biopharma, Inc.股票出现波动，股价急速下挫5.06%。Arrivent Biopharma, Inc.股票所在的生物技术行业中，整体跌幅为1.39%。Arrivent Biopharma, Inc.公司简介：ArriVent BioPharma Inc 是一家临床阶段的生物制药公司，致力于识别、开发和商业化差异化药物，以解决癌症患者未满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110231325a21d189a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250110231325a21d189a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2501636862","title":"Arrivent Biopharma, Inc.盘中异动 股价大跌5.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2501636862","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501636862?lang=zh_cn&edition=full","pubTime":"2025-01-07 02:04","pubTimestamp":1736186695,"startTime":"0","endTime":"0","summary":"北京时间2025年01月07日02时04分，Arrivent Biopharma, Inc.股票出现波动，股价大幅下挫5.52%。Arrivent Biopharma, Inc.股票所在的生物技术行业中，整体涨幅为0.37%。Arrivent Biopharma, Inc.公司简介：ArriVent BioPharma Inc 是一家临床阶段的生物制药公司，致力于识别、开发和商业化差异化药物，以解决癌症患者未满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010702045595fa990f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010702045595fa990f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AVBP"],"gpt_icon":0},{"id":"2491353465","title":"Arrivent Biopharma, Inc.盘中异动 下午盘快速下跌5.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491353465","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491353465?lang=zh_cn&edition=full","pubTime":"2024-12-13 02:52","pubTimestamp":1734029558,"startTime":"0","endTime":"0","summary":"北京时间2024年12月13日02时52分，Arrivent Biopharma, Inc.股票出现异动，股价大幅跳水5.25%。Arrivent Biopharma, Inc.股票所在的生物技术行业中，整体跌幅为1.05%。Arrivent Biopharma, Inc.公司简介：ArriVent BioPharma Inc 是一家临床阶段的生物制药公司，致力于识别、开发和商业化差异化药物，以解决癌症患者未满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121302523895e93fcf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121302523895e93fcf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AVBP","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://arrivent.com","stockEarnings":[{"period":"1week","weight":-0.0717},{"period":"1month","weight":-0.0968},{"period":"3month","weight":0.1224},{"period":"6month","weight":-0.0024},{"period":"1year","weight":-0.2312},{"period":"ytd","weight":-0.2222}],"compareEarnings":[{"period":"1week","weight":-0.0014},{"period":"1month","weight":0.0053},{"period":"3month","weight":0.0278},{"period":"6month","weight":0.0986},{"period":"1year","weight":0.1679},{"period":"ytd","weight":0.1722}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Arrivent Biopharma, Inc.于2021年4月14日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，致力于差异化药物的识别、开发和商业化，以解决癌症患者未满足的医疗需求。该公司寻求利用团队深厚的药物开发经验，通过在患有癌症的患者中获得批准和商业化，最大限度地发挥先导开发候选药物呋莫替尼的潜力，并推进一系列新疗法，例如下一代抗体药物偶联物，最初的重点是实体瘤。","exchange":"NASDAQ","name":"ArriVent BioPharma","nameEN":"ArriVent BioPharma"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ArriVent BioPharma(AVBP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ArriVent BioPharma(AVBP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ArriVent BioPharma,AVBP,ArriVent BioPharma股票,ArriVent BioPharma股票老虎,ArriVent BioPharma股票老虎国际,ArriVent BioPharma行情,ArriVent BioPharma股票行情,ArriVent BioPharma股价,ArriVent BioPharma股市,ArriVent BioPharma股票价格,ArriVent BioPharma股票交易,ArriVent BioPharma股票购买,ArriVent BioPharma股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ArriVent BioPharma(AVBP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ArriVent BioPharma(AVBP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}